Toxicity and response to thiopurines in patients with inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 7, 2015, Pages 891-900

  Goldberg, Rimma ^a,b   Irving, Peter M ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

azathioprine; IBD; mercaptopurine; thiopurine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MESALAZINE; PANCREAS ENZYME; PLACEBO; TIOGUANINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE;

ABDOMINAL SURGERY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW DISEASE; BONE MARROW TOXICITY; CANCER RISK; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; EVIDENCE BASED MEDICINE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEALING; HEALTH EDUCATION; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES ZOSTER; HUMAN; INFLAMMATORY BOWEL DISEASE; LISTERIOSIS; LIVER DYSFUNCTION; LIVER HYPERPLASIA; LIVER TOXICITY; LYMPHOMA; MALAISE; MULTICENTER STUDY (TOPIC); MYALGIA; MYCOPLASMA PNEUMONIA; NAUSEA; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT MONITORING; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; ULCERATIVE COLITIS; VAGINITIS; VIRUS PNEUMONIA; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; DRUG-INDUCED LIVER INJURY; NEOPLASM; NEUTROPENIA;

6-MERCAPTOPURINE; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NAUSEA; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PANCREATITIS;

EID: 84931837855     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1039987     Document Type: Article

References (83)

1. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:70-13
2. Neurath MF, Kiesslich R, Teichgraber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 2005;3: 1007-14
3. Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010;4:575-88
4. Ben-Horin S, Goldstein I, Fudim E, et al. Early preservation of effector functions followed by eventual T cell memory depletion: A model for the delayed onset of the effect of thiopurines. Gut 2009;58: 396-403
5. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;Cd000545
6. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42
7. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9: Cd000478
8. Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145: 766-74; e1
9. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of crohn's disease: A randomized controlled trial. Gastroenterology 2013;145:758-65; e2
10. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
11. Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015. [Epub ahead of print]
12. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-18
13. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: A high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-5
14. Kennedy NA, Kalla R, Warner B, et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014;40(11-12):1313-23
15. Moreau AC, Paul S, Del Tedesco E, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: A meta-analysis. Inflamm Bowel Dis 2014;20:464-71
16. Smith M, Blaker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013;67:161-9
17. Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53:1306-14
18. Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther 2014;39:163-75
19. Bouguen G, Sninsky C, Tang KL, et al. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: A post hoc analysis from SONIC. Inflamm Bowel Dis 2015; 21(3):606-14
20. Kopylov U, Battat R, Benmassaoud A, et al. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. Dig Dis Sci 2015;60:478-84
21. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15:375-82
22. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011;60:930-6
23. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41
24. Chatu S, Subramanian V, Saxena S, et al. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: A systematic review and meta-analysis. Am J Gastroenterol 2014;109:23-34; quiz 35
25. Chhaya V, Saxena S, Cecil E, et al. Impact of timing and duration of thiopurine treatment on first perianal surgery in crohn's disease: UK Population-based Study (1995-2009). Inflamm Bowel Dis 2015;21: 385-91
26. Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut 2014;63:1695-9
27. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009;104:2760-7
28. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400; e3
29. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53
30. Gisbert JP, Nino P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28:228-38
31. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012;61:235-40
32. Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1324-9
33. Jess T, Lopez A, Andersson M, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: A meta-analysis. Clin Gastroenterol Hepatol 2014;12(11):1793-800
34. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993;68:186-90
35. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181-9
36. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003;98:1058-63
37. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125: 298-303
38. Ansari A, Elliott T, Fong F, et al. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm Bowel Dis 2008;14:1399-405
39. Seinen ML, van Asseldonk DP, Mulder CJ, et al. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. J Gastrointestin Liver Dis 2010;19:291-4
40. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013;19: 1404-10
41. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut 2002;50:485-9
42. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010;16:1541-9
43. Costantino G, Furfaro F, Belvedere A, et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis 2012;6:588-96
44. Stocco G, Martelossi S, Barabino A, et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:57-64
45. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:640-7
46. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:973-83
47. Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther 2013;38:1255-66
48. Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:654-61
49. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:220-7
50. Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: A novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012;36:449-58
51. Bell BA, Brockway GN, Shuster JJ, et al. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: A Pediatric Oncology Group study (now The Children's Oncology Group). Pediatr Blood Cancer 2004;43:105-9
52. Mazor Y, Koifman E, Elkin H, et al. Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. Curr Drug Saf 2013;8:181-5
53. Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008;28:623-8
54. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. 2014;46:1131-4
55. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review. Am J Gastroenterol 2008;103: 1783-800
56. Lewis JD, Abramson O, Pascua M, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 2009;7:1195-201; quiz 1141-2
57. de Boer NK, van Bodegraven AA, Jharap B, et al. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4:686-94
58. Roblin X, Peyrin-Biroulet L, Phelip JM, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008;103:3115-22
59. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30
60. Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017-20
61. Seksik P, Mary JY, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis 2011;17:565-72
62. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:734-41
63. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004;75:274-81
64. Nguyen TV, Vu DH, Nguyen TM, et al. Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis. Ther Drug Monit 2013;35:251-7
65. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15
66. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012;6:905-12
67. Ferlitsch A, Teml A, Reinisch W, et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol 2007;102:2495-503
68. Pavlidis P, Ansari A, Duley J, et al. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: A 2-center observational cohort study. Inflamm Bowel Dis 2014;20:2239-46
69. De Boer NK, Tuynman H, Bloemena E, et al. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008;43:604-8
70. Seksik P, Cosnes J, Sokol H, et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 2009;29:1106-13
71. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134: 929-36
72. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
73. Nguyen T, Vacek PM, O'Neill P, et al. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res 2009;69:7004-12
74. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4
75. Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:119-30
76. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009;374:1617-25
77. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: A nationwide retrospective cohort study. Gastroenterology 2013;145:1007-15; e3
78. Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013;177:1296-305
79. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8; e1-5
80. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014;146:941-9
81. Jess T, Horvath-Puho E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: A Danish population-based cohort study. Am J Gastroenterol 2013;108: 1869-76
82. Rungoe C, Simonsen J, Riis L, et al. Inflammatory bowel disease and cervical neoplasia: A population-based nationwide cohort study. Clin Gastroenterol Hepatol 2014;13(4):693-700
83. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-35; quiz 1436